Kaleido Biosciences, Inc. engages in the provision of healthcare services. It focuses on leveraging the microbiome organ to treat disease and improve human health. Read More It offers microbiome metabolic therapies (MMT) which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of the organ's existing microbes. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan in 2015 and is headquartered in Lexington, MA. The listed name for KLDO is Kaleido Biosciences, Inc. Common Stock.